
## Current Validation Status



**Current State**: The pipeline has been functionally tested and verified to produce all expected outputs according to specifications. However, **formal validation against ground-truth datasets has not yet been performed**. This is a critical next step before clinical deployment.

### What Has Been Completed

1. **Functional Testing**: 
   - Pipeline executes all 5 stages successfully
   - All required outputs are generated
   - Code compliance with specifications verified (100%)
   - Single test sample processed: `RAR001_00482087_MGM2718_1__9221147`

2. **Output Verification**:
   - All expected file formats generated
   - File sizes and structures validated
   - No runtime errors or crashes

3. **Code Review**:
   - Implementation matches specifications
   - All algorithms implemented correctly (KS test, 2×VAF, etc.)

---

## Proposed Validation Strategy

### 1. Validation Dataset Options

#### Option A: Published Benchmarks (Recommended)
- **ichorCNA Validation Dataset**: 
  - Use samples from Adalsteinsson et al. (2017) with known tumor fractions
  - Publicly available cfDNA samples with clinical annotations
  - Known CNV profiles from matched tumor tissue

- **TCGA/Public Datasets**:
  - Use publicly available ctDNA datasets with ground-truth annotations
  - Examples: COSMIC, ICGC datasets with matched tumor/normal pairs

#### Option B: Internal Clinical Dataset
- **If Available**: Use your institution's clinically validated samples
  - Samples with known ctDNA fraction from clinical testing
  - Matched tumor tissue for CNV validation
  - Samples with known variant profiles

#### Option C: Synthetic/Spike-in Validation
- **Synthetic Mixtures**: 
  - Create known tumor/normal DNA mixtures at defined ratios (e.g., 1%, 3%, 5%, 10%)
  - Validate tumor fraction estimation accuracy
  - Test CNV detection sensitivity

### 2. Performance Metrics to Calculate

#### For Tumor Fraction Estimation (ichorCNA):
- **Concordance**: Correlation coefficient (R²) between estimated and known tumor fraction
- **Accuracy**: Mean absolute error (MAE) and root mean square error (RMSE)
- **Bias**: Systematic over/under-estimation at different tumor fractions
- **Precision**: Coefficient of variation (CV) for replicate samples
- **Sensitivity**: Detection rate at low tumor fractions (e.g., <3%, <1%)

#### For CNV Detection:
- **Sensitivity**: True positive rate for known CNVs
- **Specificity**: True negative rate (absence of CNVs)
- **Concordance**: Agreement with matched tumor tissue CNV profiles
- **Copy Number Accuracy**: Accuracy of estimated copy number states

#### For Variant Calling (Mutect2):
- **Sensitivity**: Detection rate of known variants
- **Specificity**: False positive rate
- **VAF Accuracy**: Correlation between estimated and known VAF
- **Fragmentomics Validation**: 
  - Confirmation that tumor-derived variants show shorter fragments (KS test p < 0.05)
  - Validation that "2 × VAF" calculation improves purity estimates at low tumor burden

#### For Fragmentomics:
- **90-150 bp Ratio**: Correlation with known ctDNA quality metrics
- **KS Test Performance**: Validation that shorter fragments correctly identify tumor-derived variants

### 3. Validation Process

#### Phase 1: Algorithm Validation (Recommended First Step)
1. **ichorCNA Validation**:
   - Use published ichorCNA validation datasets
   - Compare our implementation's output with published results
   - Validate tumor fraction estimates against ground truth

2. **Fragmentomics Validation**:
   - Use samples with known variant profiles
   - Validate that KS test correctly identifies tumor-derived variants
   - Confirm fragment length differences between ALT and REF alleles

#### Phase 2: End-to-End Pipeline Validation
1. **Multi-Sample Testing**:
   - Process 10-20 samples with known ground truth
   - Calculate all performance metrics
   - Generate validation report

2. **Clinical Concordance**:
   - Compare pipeline results with clinical test results (if available)
   - Validate against matched tumor tissue profiles

#### Phase 3: Reproducibility Testing
1. **Replicate Analysis**: 
   - Process same samples multiple times
   - Assess reproducibility and precision

2. **Cross-Platform Validation**:
   - Test on different sequencing platforms (if applicable)
   - Validate consistency across platforms

3. **Comparison with Ground Truth**:
   - Concordance tables
   - Scatter plots (estimated vs. known)
   - ROC curves (if applicable)

4. **Limitations and Recommendations**:
   - Known limitations
   - Recommended use cases
   - Areas for improvement








